← Oncology Approval Tracker

FDA DECISION ·

Rituxan + chemotherapy

rituximab with chemotherapy · Genentech

FDA approvalNew or expanded indicationPediatric B-cell lymphoma and leukemia
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Children aged 6 months to under 18 years with previously untreated, advanced CD20-positive DLBCL, Burkitt or Burkitt-like lymphoma, or mature B-cell acute leukemia.

LAMPGEN ANALYSIS

Why it matters

This adds rituximab to chemotherapy for specified pediatric CD20-positive malignancies.

What research teams should watch

Document CD20 result, histology, stage and age, and coordinate infusion reactions and infection surveillance.

PRIMARY RECORDS

Sources